Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

BURROUGHS-WELLCOME's SUDAFED/ACTIFED SALES IN U.S. TOPPED $120 MIL. in 1985, according to product information included in a registration statement for Wellcome's initial stock plan. "In the U.S., Actifed and Sudafed are the market leaders in the OTC antihistamine/decongestant category," the prospectus notes. "This market is highly competitive but, as a result of an aggressive marketing campaign, Wellcome has achieved growth in dollar terms in combined sales of these two products of 74% over the past two years and in 1985 the U.S. market accounted for approximately 70% of the group's sales in this product area." The British firm reported that combined sales of Actifed and Sudafed in 1985 were (BRITISH POUND)142 mil. worldwide, up 38% from (BRITISH POUND)103 mil. in 1984. At 70% of worldwide sales, U.S. Actifed and Sudafed revenues would total approximately (BRITISH POUND)100 mil., or $122.5 mil., based on the exchange rate for 1985 used in the prospectus. Wellcome said that further growth of its U.S. OTC cough/cold business "is expected, but at a slower rate." In the U.K., Wellcome noted the company has only two drug preparations in the cough/cold area that can be prescribed on the Natl. Health Service: Sudafed elixir and tablets. The prospectus explains that this situation is the result of restrictions imposed by the British government last April on the number of drugs in certain therapeutic categories that can be prescribed by doctors for Natl. Health Service patients. "These restrictions have resulted in the loss of sales of certain Wellcome products, most notably Actifed, which have ceased to be prescribable on the NHS but this has been partly offset by the beneficial effect on sales of Sudafed elixir and tablets," the company said. "Promotional restrictions applicable to prescribable products no longer apply to Actified," the firm added, "and Wellcome is now undertaking a campaign on television and by other means along the lines of its successful U.S. marketing efforts to promote sales in the U.K. through the OTC market." Wellcome's Actifed/Sudafed sales represented approximately 17% of the firm's total health care revenues of (BRITISH POUND)825 mil. in 1985, or approximately $1.01 bil. In pounds sterling, sales from Wellcome's human health care products segment were up 21% in 1985, boosting trading profit from the segment 41% to (BRITISH POUND)138 mil. Overall, Wellcome reported sales over (BRITISH POUND)1 bil. in 1985, up 25%, with net profit increasing 45.2% to (BRITISH POUND)68.7 mil. Based on average currency exchange values for 1985 cited in the prospectus, Wellcome sales and net income translate into $1.23 bil. and $84.2 mil., respectively. Wellcome's initial public offering consists of 210.8 mil. shares at a U.K. offer price of 120p per share. The offer includes 168 mil. shares offered by the Wellcome Trust and another 42.8 mil. shares offered by the company. Wellcome PLC is offering its shares to eligible employees and retired employees at 25p each. At the 120p U.K. offer price, the shares arre worth approximately $1.69 each, or a total of $72.3 mil. for the company's 42.8 mil. shares.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts